Literature DB >> 9042628

Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.

A G Wong1, A D O'Shaughnessy, C M Walker, M R Sears.   

Abstract

Regular use of short-acting beta-agonists may decrease control of asthma and increase airway responsiveness to bronchoconstrictor stimuli. The aim of this study was to determine the effects of regular treatment with the long-acting beta-agonist, salmeterol, on the methacholine dose-response curve (DRC) in mild-to-moderate asthmatics. Changes in methacholine airway responsiveness were measured in 14 stable adult asthmatics, randomized in a double-blind, three-way cross-over design to receive salmeterol 50 micrograms, salbutamol 200 micrograms or placebo, each twice daily for 4 days. Two baseline methacholine DRC, were performed, one without premedication and one following a single dose of 200 micrograms salbutamol. Following 4 days of regular treatment, methacholine DRC to plateau were carried out commencing 15 min after the final dose of trial medication. There were no significant differences in mean baseline forced expiratory volume in one second (FEV1) between treatments. Four days treatment with salmeterol and salbutamol shifted the DRC to the right, but salmeterol provided less protection than salbutamol. The point of inflection of the curve from baseline moved 1.9 and 3.2 doubling doses, respectively, compared to placebo (p < or = 0.001), and the provocative concentration of methacholine required to produce a 20% fall in FEV1 (PC20) increased 1.6 and 3.1 doubling doses, respectively (p < or = 0.001). The slope of the DRC was increased slightly by both beta-agonists compared to placebo (log slope 3.11, 3.06 and 2.77 for salmeterol, salbutamol and placebo, respectively). This effect of regular salmeterol on slope was more marked in subjects with lower baseline FEV1. Maximal response plateaus did not differ between the three treatments. These results suggest that regular use either of short- or long-acting beta-agonists could increase the risk of a more precipitous asthma episode associated with "breakthrough" bronchoconstrictor responses, particularly in those with more severe initial airflow obstruction, if subjects are exposed to a sufficiently potent stimulus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042628     DOI: 10.1183/09031936.97.10020330

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

Authors:  E H Walters; J A Walters; P W Gibson
Journal:  Cochrane Database Syst Rev       Date:  2002

2.  Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle.

Authors:  Gustavo Nino; Aihua Hu; Judith S Grunstein; Michael M Grunstein
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-07       Impact factor: 5.464

Review 3.  Beta2-agonists and bronchial hyperresponsiveness.

Authors:  Clive P Page; Domenico Spina
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 4.  Airways reactivity in patients with CF.

Authors:  Miles Weinberger
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 5.  Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma.

Authors:  Gustavo Nino; Michael M Grunstein
Journal:  Curr Opin Pediatr       Date:  2010-06       Impact factor: 2.856

Review 6.  Methacholine challenge testing: comparative pharmacology.

Authors:  Beth E Davis; Christianne M Blais; Donald W Cockcroft
Journal:  J Asthma Allergy       Date:  2018-05-14

7.  The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.

Authors:  Christianne M Blais; Beth E Davis; Donald W Cockcroft
Journal:  Respir Res       Date:  2017-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.